Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Endocrinology | Gastroenterology | Neurology | Nursing | Oncology | Pharmacy | Journal

Back to Journal Articles

Chemo Combo Promising for Pancreatic Neuroendocrine Tumors

Last Updated: July 13, 2012.

 

Greater benefit with temozolomide, bevacizumab for patients with pancreatic versus carcinoid NETs

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
The combination of temozolomide and bevacizumab seems to benefit patients with advanced pancreatic neuroendocrine tumors, according to a study published online July 9 in the Journal of Clinical Oncology.

FRIDAY, July 13 (HealthDay News) -- The combination of temozolomide and bevacizumab seems to benefit patients with advanced pancreatic neuroendocrine tumors (NETs), according to a study published online July 9 in the Journal of Clinical Oncology.

Jennifer A. Chan, M.D., M.P.H., from the Dana-Farber Cancer Institute in Boston, and colleagues conducted a phase II study in which they treated 34 patients with NETs (56 percent carcinoid; 44 percent pancreatic NETs) with temozolomide in combination with bevacizumab.

The researchers found that the combination of temozolomide and bevacizumab correlated with expected grade 3 to 4 toxicities, including lymphopenia (53 percent) and thrombocytopenia (18 percent). The radiographic response rate was 15 percent overall, and was 33 percent for patients with pancreatic NETs, compared with 0 percent for those with carcinoid tumors. Progression-free survival was a median of 11.0 months (14.3 months for pancreatic NETs versus 7.3 months for carcinoid tumors). Overall survival was a median of 33.3 months (41.7 months for pancreatic NETs versus 18.8 months for carcinoid tumors).

"Temozolomide and bevacizumab can be safely administered together in patients with advanced NETs, and the combination regimen appears promising for patients with pancreatic NETs," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Genentech and Schering-Plough/Merck, which funded the study and manufacture bevacizumab and temozolomide.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Hypertrophy Common in Older Patients With Port-Wine Stains Next: Quality Care Demonstrated at Federally Qualified Health Centers

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.